Signaling mechanisms of basic fibroblast growth factor in arterial cells from genetically hypertensive rat.
The mechanisms of vascular structural alterations in hypertension were studied in cultured adventitial fibroblasts isolated from aortas of spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats. Basic fibroblast growth factor (bFGF)-, epidermal growth factor (EGF)-, or platelet-derived growth factor (PDGF)-induced DNA synthesis and phospholipase C activity were estimated by determining 3H-thymidine incorporation and 3H-inositol phosphate production, respectively. The role of protein tyrosine kinases was assessed by stimulating the cells in the presence of tyrphostin, a protein tyrosine kinase inhibitor. Both the mitogenic potency of bFGF, EGF, and PDGF and the phospholipase C activity elicited by these factors were increased markedly in SHR (v WKY) fibroblasts. SHR fibroblasts were significantly less sensitive to tyrphostin inhibition of bFGF-induced 3H-thymidine incorporation than WKY fibroblasts, whereas when the cells were stimulated with EGF, PDGF, or 5% serum, SHR and WKY fibroblasts were equally sensitive to tyrphostin inhibition. At doses that abolished bFGF-induced 3H-thymidine incorporation, tyrphostin did not affect bFGF-induced 3H-inositol phosphate production. These results indicate that in aortic fibroblasts phospholipase C activation is not sufficient for bFGF-induced DNA synthesis. They suggest that tyrosine kinase activation is a necessary step in the transduction of bFGF mitogenic signal and plays an important role in the enhanced DNA synthesis exhibited by SHR (v WKY) cells. Therefore, one may envisage that bFGF contributes, through paracrine/autocrine mechanisms, to the vascular smooth muscle hyperplasia/hypertrophy in SHR.
Zhu
D L
DL
CNRS URA 1482, Laboratoire de Pharmacologie, Faculté de Médecine Necker, Paris, France.
Hérembert
T
T
Caruelle
D
D
Caruelle
J P
JP
Marche
P
P
D000818:Animals; D001011:Aorta; D001158:Arteries / Q000166:cytology / Q000502:physiology*; D002396:Catechols / Q000494:pharmacology; D004247:DNA / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology / Q000502:physiology*; D005347:Fibroblasts / Q000378:metabolism; D006973:Hypertension / Q000378:metabolism*; D008297:Male; D009570:Nitriles / Q000494:pharmacology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D015398:Signal Transduction; D013936:Thymidine / Q000037:antagonists & inhibitors / Q000378:metabolism; D010738:Type C Phospholipases / Q000378:metabolism; D020032:Tyrphostins
D002396:Catechols; D009570:Nitriles; D010982:Platelet-Derived Growth Factor; D020032:Tyrphostins; D016222:Fibroblast Growth Factor 2; C060152:tyrphostin 47; D004815:Epidermal Growth Factor; D004247:DNA; D011505:Protein-Tyrosine Kinases; D010738:Type C Phospholipases; D013936:Thymidine